SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-163
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of November 2026
Commission File Number: 000-49843
Alterity Therapeutics Limited
(Name of Registrant)
Level 15, 500 Collins Street, Melbourne, Victoria 3000 Australia
(Address of Principal Executive Office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Change in Registrant’s Certifying Accountant
Alterity Therapeutics Limited (the “Company”) is furnishing this current report on Form 6-K (“Form 6-K”) to report that following shareholder approval at the 2026 Annual General Meeting, PricewaterhouseCoopers (the “Former Auditor” or “PwC”) has resigned as the Company’s independent registered public accounting firm effective November 20, 2026, and that the Company has appointed BDO Audit Pty Ltd (the “Successor Auditor”) as successor auditor of the Company effective the same date.
In connection with the change in auditor, the Company provides that:
| |
1.
|
The Company’s shareholders, on November 20, 2026, have approved the resignation of the Former Auditor and the appointment of the Successor Auditor as the independent registered public accounting firm of the Company for the financial year ending June 30, 2027.
|
| |
2.
|
For the fiscal years ended June 30, 2026 and 2025, PwC did not issue any reports on the consolidated financial statements of the Company that contained an adverse opinion or a disclaimer of opinion, nor were the auditors’ reports of PwC qualified or modified as to uncertainty, audit scope, or accounting principles.
|
| |
3.
|
During the fiscal years ended June 30, 2026 and 2025 and the subsequent interim period through November 20, 2026, there were no disagreements, as defined in Item 16F(a)(1)(iv) of Form 20-F and the related instructions to Item 16F of Form 20-F, between the Company and the Former Auditor on any matter of accounting principles or practices, financial statement disclosures, or auditing scope or procedures, which disagreements if not resolved to the Former Auditor’s satisfaction would have caused the Former Auditor to make reference to the subject matter of the disagreement in connection with its auditors’ reports, or any “reportable events”, as that term is described in Item 16F(a)(1)(v) of Form 20-F.
|
During the fiscal years ended June 30, 2026 and 2025 and the subsequent interim period through November 20, 2026, neither the Company nor anyone on its behalf have consulted with the Successor Auditor on either (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company’s financial statements, and neither a written report was provided to the Company nor oral advice was provided that the Successor Auditor concluded was an important factor considered by the Company in reaching a decision as to the accounting, auditing or financial reporting issue; or (ii) any matter that was the subject of a disagreement, as that term is defined in Item 16F(a)(1)(iv) of Form 20-F and the related instructions to Item 16F of Form 20-F, or a reportable event as set forth in Item 16F(a)(1)(v) of Form 20-F.
The Company has provided the Former Auditor with a copy of the disclosures made in this Form 6-K and has requested that the Former Auditor provides the Company with a letter addressed to the Securities and Exchange Commission stating whether they agree with the statements contained herein and, if not, stating the respects in which they do not agree. A copy of the Former Auditor’s letter dated November 20, 2026 is furnished as Exhibit 99.1 to this Form 6-K.
The Company intends to use this Form 6-K and the accompanying exhibit to satisfy its reporting obligations under Item 16F(a) of its Form 20-F for the year ending June 30, 2027 to the extent provided in and permitted by Paragraph 2 of the Instructions to Item 16F of Form 20-F, and plans to incorporate Exhibit 99.1 by reference into its Form 20-F to the extent necessary to satisfy such reporting obligations.
EXHIBITS
The following exhibits are submitted:
|
99.1
|
Letter of PricewaterhouseCoopers, dated November 20, 2026 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| |
Alterity Therapeutics Limited
|
| |
|
|
| |
By:
|
/s/ Julian Babarczy
|
| |
|
Julian Babarczy
|
| |
|
Chairman
|
Date: November 20, 2026
Exhibit 99.1

November 20, 2026
Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549
Commissioners:
We have read the statements made by Alterity Therapeutics Limited (copy attached), which we understand will be filed with the Securities and Exchange Commission, pursuant to Form 6-K concerning the change in its certifying accountant and provided in response to Item 16F(a) of Form 20-F of Alterity Therapeutics Limited dated November 20, 2026. We agree with the statements concerning our Firm contained therein.
Very truly yours
/s/ PricewaterhouseCoopers
Melbourne, Australia
Attachment
|
pwc.com.au
|
PricewaterhouseCoopers, ABN 52 780 433 757
2 Riverside Quay, SOUTHBANK VIC 3006,
GPO Box 1331 MELBOURNE VIC 3001
T: +61 3 8603 1000, F: +61 3 8603 1999, www.pwc.com.au
Liability limited by a scheme approved under Professional Standards Legislation.
|